Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 5/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23135666 | 0.83 | CTSL (0.44) | CTSLOPRD1OPRM1OPRK1FOLH1 | |
| SCHEMBL18879461 | 0.82 | GRIA1 (0.44) | CTSLOPRD1OPRM1OPRK1FOLH1 | |
| SCHEMBL23026392 | 0.82 | CTSL (0.49) | CTSLOPRD1OPRM1OPRK1FOLH1 | |
| SCHEMBL19700517 | 0.81 | FOLH1 (0.45) | CTSLOPRD1OPRM1OPRK1FOLH1 | |
| SCHEMBL20099253 | 0.80 | ACE (0.46) | CTSLOPRD1OPRM1OPRK1FOLH1 | |
| SCHEMBL19871860 | 0.76 | OPRD1 (0.39) | CTSLOPRD1OPRM1OPRK1FOLH1 | |
| SCHEMBL18973012 | 0.75 | MAPT (0.44) | MMEACECPA1ACE2 | |
| SCHEMBL21503815 | 0.69 | ACE (0.48) | CTSLMMEACECTSSCTSK | |
| SCHEMBL21415384 | 0.69 | GRIA1 (0.46) | CTSLOPRD1OPRM1OPRK1FOLH1 | |
| SCHEMBL16217709 | 0.69 | GRIA1 (0.46) | CTSLOPRD1OPRM1OPRK1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | CTSL 2979/4885OPRD1 3061/4885OPRM1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.